Yamamoto, N., Mera, T., Märten, A., & Hochmair, M. J. (2019). Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib. Adv Ther.
استشهاد بنمط شيكاغوYamamoto, Nobuyuki, Takeshi Mera, Angela Märten, و Maximilian J. Hochmair. "Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated With a 40-mg Starting Dose of Afatinib." Adv Ther 2019.
MLA استشهادYamamoto, Nobuyuki, Takeshi Mera, Angela Märten, و Maximilian J. Hochmair. "Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated With a 40-mg Starting Dose of Afatinib." Adv Ther 2019.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.